ImmuPharma plc (AIM: IMM) has filed an international Patent Cooperation Treaty application covering its P140 precision medicine approach to autoimmune disease, including identifying and treating patients with the Type M immune
ImmuPharma Appoints Kymos Group to Support Kapiglucagon Development
ImmuPharma plc (AIM: IMM) has appointed Kymos Group as its bioanalytical contract research organisation partner for the development of Kapiglucagon, its proprietary glucagon prodrug for Type 1 diabetes applications.
ImmuPharma appoints Thermo Fisher for drug production
ImmuPharma (AIM: IMM) has appointed Thermo Fisher Scientific to develop and manufacture the finished drug form of Kapiglucagon, its experimental diabetes treatment.
RNS Hotlist with Zak Mir: IMM, INT, HREE, ORR, ENSI & MPE
(Alliance News) – Stocks in London are set to open higher on Wednesday, ahead of the UK releasing its consumer, producer and retail price inflation data for June. Single bus fares
Share Talk Weekly Stock Market News Review, Sunday 28th June 2026
London’s leading stock indices ended the week on a subdued note, with the FTSE 100 edging lower after briefly trading near a two-month high. The blue-chip index closed down 21.87
RNS Hotlist with Zak Mir: QHE, AVCT, MPL, CASP, IMM, BVC, APTA, EZJ, ORCP, TRP & ZIN
Quantum Helium Limited (QHE) provided shareholders with a review of the key milestones achieved over the past twelve months ahead of the Company’s Extraordinary General Meeting (“EGM”), which is scheduled to
ImmuPharma highlights brain cancer potential for P140
ImmuPharma (AIM: IMM) has highlighted new academic research suggesting its lead drug candidate, P140, may have potential as a treatment for glioblastoma, one of the most aggressive and difficult-to-treat forms
Share Talk Weekly Stock Market News Review, Sunday 12th April 2026
It has been a strong week for the UK’s growth companies, with the AIM All-Share—widely seen as the benchmark for smaller-cap stocks—rising 4.5% as investors looked through geopolitical uncertainty and
ImmuPharma advances P140 partnering strategy following £6.5m raise
ImmuPharma PLC (AIM: IMM) said it is actively progressing partnering discussions for its lead autoimmune platform, P140, which remains its primary strategic focus for 2026.
RNS Hotlist with Zak Mir: ZEN, LST, THX, RMR, GSCU, ASTR, IMM, SWC, SEEN, MKA, ITM, AVCT, EGT, MBO & WSBN
Zenith Energy Ltd. (ZEN) announced the appointment of Mr. Charles Michel, the former President of the European Council (2019-2024) and former Prime Minister of Belgium (2014-2019), to further strengthen the legal
Share Talk Weekly Stock Market News Review, Sunday 29th March 2026
The AIM All-Share slipped slightly on the week and is now down around 7% year-to-date, underlining the pressure on smaller companies. In contrast, the FTSE 100 closed the week at 9,967, slipping just 5
RNS Hotlist with Zak Mir: IMM, KEN, 80M, GROC, EOG, HREE, MWE, 88E & ROAD
ImmuPharma PLC (IMM), the specialist drug discovery and development company, provided an update on its auto-immune technology platform program, P140. IMM said “The receipt of the first Combined Search and Examination